bluebird bio (NASDAQ:BLUE) Lifted to Hold at BidaskClub
Several other equities research analysts have also recently weighed in on BLUE. Evercore ISI cut bluebird bio from an outperform rating to an in-line rating in a research report on Wednesday, November 27th. Oppenheimer raised bluebird bio from a market perform rating to an outperform rating and set a $135.00 price objective for the company in a research report on Thursday, December 12th. Cowen reissued a buy rating on shares of bluebird bio in a research report on Friday, December 6th. Wells Fargo & Co reduced their price objective on bluebird bio from $242.00 to $160.00 and set an overweight rating for the company in a research report on Monday, December 9th. Finally, William Blair reissued a hold rating on shares of bluebird bio in a research report on Tuesday, December 10th. Eight equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company’s stock. bluebird bio presently has an average rating of Buy and a consensus target price of $136.56.
BLUE opened at $98.04 on Friday. bluebird bio has a 1-year low of $71.42 and a 1-year high of $163.43. The company has a current ratio of 6.22, a quick ratio of 6.22 and a debt-to-equity ratio of 0.12. The stock has a market capitalization of $5.42 billion, a price-to-earnings ratio of -7.55 and a beta of 2.37. The business has a 50 day moving average of $89.06 and a 200-day moving average of $99.74.
In other news, insider Kory James Wentworth sold 397 shares of the company’s stock in a transaction dated Thursday, December 19th. The shares were sold at an average price of $92.59, for a total transaction of $36,758.23. Following the completion of the transaction, the insider now owns 6,449 shares in the company, valued at $597,112.91. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Philip D. Gregory sold 1,800 shares of the stock in a transaction dated Tuesday, December 17th. The shares were sold at an average price of $94.31, for a total transaction of $169,758.00. Following the completion of the transaction, the insider now owns 30,892 shares of the company’s stock, valued at approximately $2,913,424.52. The disclosure for this sale can be found here. Insiders sold 13,977 shares of company stock worth $1,263,376 over the last ninety days. 3.00% of the stock is currently owned by corporate insiders.
Hedge funds and other institutional investors have recently modified their holdings of the business. CSat Investment Advisory L.P. purchased a new stake in bluebird bio during the second quarter valued at about $31,000. Rational Advisors LLC grew its holdings in bluebird bio by 532.3% during the third quarter. Rational Advisors LLC now owns 392 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 330 shares during the last quarter. NuWave Investment Management LLC grew its holdings in bluebird bio by 398.7% during the third quarter. NuWave Investment Management LLC now owns 788 shares of the biotechnology company’s stock valued at $71,000 after purchasing an additional 630 shares during the last quarter. Nisa Investment Advisors LLC grew its holdings in bluebird bio by 2,020.0% during the third quarter. Nisa Investment Advisors LLC now owns 1,060 shares of the biotechnology company’s stock valued at $97,000 after purchasing an additional 1,010 shares during the last quarter. Finally, Tower Research Capital LLC TRC boosted its position in shares of bluebird bio by 87.1% in the second quarter. Tower Research Capital LLC TRC now owns 810 shares of the biotechnology company’s stock valued at $103,000 after acquiring an additional 377 shares during the period.
About bluebird bio
bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates in severe genetic diseases include LentiGlobin, which is in various clinical studies for the treatment of transfusion-dependent ß-thalassemia and severe sickle cell disease; and Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder.
Featured Story: Closed-End Mutual Funds
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.